Main variables	No. of employees	Total
No. of companies carrying out R&D in Biotechnology	Fewer than 250 employees	1.155
No. of companies carrying out R&D in Biotechnology	250 or more employees	145
No. of companies carrying out R&D in Biotechnology	Total 2021	1.299
%Companies according to biotechnology used: Genetic code	Fewer than 250 employees	29,7
%Companies according to biotechnology used: Genetic code	250 or more employees	39,5
%Companies according to biotechnology used: Genetic code	Total 2021	30,8
%Companies according to biotechnology used: Functional units	Fewer than 250 employees	37,4
%Companies according to biotechnology used: Functional units	250 or more employees	46,5
%Companies according to biotechnology used: Functional units	Total 2021	38,4
%Companies according to biotechnology used: Cellular and tissue culturing and engineering	Fewer than 250 employees	20,1
%Companies according to biotechnology used: Cellular and tissue culturing and engineering	250 or more employees	33,3
%Companies according to biotechnology used: Cellular and tissue culturing and engineering	Total 2021	21,5
%Companies according to biotechnology used: Bioprocesses	Fewer than 250 employees	49,2
%Companies according to biotechnology used: Bioprocesses	250 or more employees	63,2
%Companies according to biotechnology used: Bioprocesses	Total 2021	50,8
%Companies according to biotechnology used: Sub-cellular organisms	Fewer than 250 employees	7,5
%Companies according to biotechnology used: Sub-cellular organisms	250 or more employees	15,9
%Companies according to biotechnology used: Sub-cellular organisms	Total 2021	8,5
%Companies according to biotechnology used: Bio-computing	Fewer than 250 employees	23,7
%Companies according to biotechnology used: Bio-computing	250 or more employees	26,4
%Companies according to biotechnology used: Bio-computing	Total 2021	24
%Companies according to biotechnology used: Nanobiotechnology	Fewer than 250 employees	12,2
%Companies according to biotechnology used: Nanobiotechnology	250 or more employees	11,1
%Companies according to biotechnology used: Nanobiotechnology	Total 2021	12,1
%Companies according to biotechnology used: Other	Fewer than 250 employees	17,2
%Companies according to biotechnology used: Other	250 or more employees	14,6
%Companies according to biotechnology used: Other	Total 2021	16,9
Companies in which biotechnology activities are: Main and/or exclusive	Fewer than 250 employees	544
Companies in which biotechnology activities are: Main and/or exclusive	250 or more employees	15
Companies in which biotechnology activities are: Main and/or exclusive	Total 2021	559
Companies in which biotechnology activities are: A secondary line of business	Fewer than 250 employees	191
Companies in which biotechnology activities are: A secondary line of business	250 or more employees	39
Companies in which biotechnology activities are: A secondary line of business	Total 2021	230
Companies in which biotechnology activities are: A tool necessary for production	Fewer than 250 employees	420
Companies in which biotechnology activities are: A tool necessary for production	250 or more employees	90
Companies in which biotechnology activities are: A tool necessary for production	Total 2021	510
%Company by field(s) of ultimate application of biotechnology use: Human Health	Fewer than 250 employees	45,9
%Company by field(s) of ultimate application of biotechnology use: Human Health	250 or more employees	42,3
%Company by field(s) of ultimate application of biotechnology use: Human Health	Total 2021	45,5
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture	Fewer than 250 employees	15,9
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture	250 or more employees	12,5
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture	Total 2021	15,5
%Company by field(s) of ultimate application of biotechnology use: Food products	Fewer than 250 employees	31,9
%Company by field(s) of ultimate application of biotechnology use: Food products	250 or more employees	35,5
%Company by field(s) of ultimate application of biotechnology use: Food products	Total 2021	32,3
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production	Fewer than 250 employees	24,1
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production	250 or more employees	20,8
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production	Total 2021	23,8
%Company by field(s) of ultimate application of biotechnology use: Environment	Fewer than 250 employees	16
%Company by field(s) of ultimate application of biotechnology use: Environment	250 or more employees	12,5
%Company by field(s) of ultimate application of biotechnology use: Environment	Total 2021	15,6
%Company by field(s) of ultimate application of biotechnology use: Industry	Fewer than 250 employees	13,9
%Company by field(s) of ultimate application of biotechnology use: Industry	250 or more employees	12,5
%Company by field(s) of ultimate application of biotechnology use: Industry	Total 2021	13,7
Personnel in R&D in biotechnology (no. of persons)	Fewer than 250 employees	9.560
Personnel in R&D in biotechnology (no. of persons)	250 or more employees	6.190
Personnel in R&D in biotechnology (no. of persons)	Total 2021	15.750
Personnel in R&D in biotechnology (no. of persons): Research personnel	Fewer than 250 employees	5.506
Personnel in R&D in biotechnology (no. of persons): Research personnel	250 or more employees	2.874
Personnel in R&D in biotechnology (no. of persons): Research personnel	Total 2021	8.379
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel	Fewer than 250 employees	4.055
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel	250 or more employees	3.316
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel	Total 2021	7.371
Personnel in R&D in biotechnology (no. of persons). Women	Fewer than 250 employees	4.963
Personnel in R&D in biotechnology (no. of persons). Women	250 or more employees	3.748
Personnel in R&D in biotechnology (no. of persons). Women	Total 2021	8.711
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel	Fewer than 250 employees	2.838
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel	250 or more employees	1.673
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel	Total 2021	4.510
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel	Fewer than 250 employees	2.125
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel	250 or more employees	2.075
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel	Total 2021	4.200
Personnel in R&D in biotechnology (FTE)	Fewer than 250 employees	6.711
Personnel in R&D in biotechnology (FTE)	250 or more employees	4.817,6
Personnel in R&D in biotechnology (FTE)	Total 2021	11.528,6
Personnel in R&D in biotechnology (FTE): Research personnel	Fewer than 250 employees	4.162,2
Personnel in R&D in biotechnology (FTE): Research personnel	250 or more employees	2.180,5
Personnel in R&D in biotechnology (FTE): Research personnel	Total 2021	6.342,7
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel	Fewer than 250 employees	2.548,8
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel	250 or more employees	2.637,1
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel	Total 2021	5.185,9
Personnel in R&D in biotechnology (FTE). Women	Fewer than 250 employees	3.575,2
Personnel in R&D in biotechnology (FTE). Women	250 or more employees	2.964,6
Personnel in R&D in biotechnology (FTE). Women	Total 2021	6.539,7
Personnel in R&D in biotechnology (FTE). Women: Research personnel	Fewer than 250 employees	2.167,4
Personnel in R&D in biotechnology (FTE). Women: Research personnel	250 or more employees	1.288,4
Personnel in R&D in biotechnology (FTE). Women: Research personnel	Total 2021	3.455,7
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel	Fewer than 250 employees	1.407,8
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel	250 or more employees	1.676,2
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel	Total 2021	3.084
Internal expenditure on R&D (thousands of euros)	Fewer than 250 employees	593.445
Internal expenditure on R&D (thousands of euros)	250 or more employees	445.137
Internal expenditure on R&D (thousands of euros)	Total 2021	1.038.582
1) By nature of the expense: Current expenses	Fewer than 250 employees	531.987
1) By nature of the expense: Current expenses	250 or more employees	408.103
1) By nature of the expense: Current expenses	Total 2021	940.091
1.1) Remuneration to research personnel	Fewer than 250 employees	194.798
1.1) Remuneration to research personnel	250 or more employees	126.772
1.1) Remuneration to research personnel	Total 2021	321.570
1.2) Remuneration to technical and auxiliary personnel	Fewer than 250 employees	91.565
1.2) Remuneration to technical and auxiliary personnel	250 or more employees	103.271
1.2) Remuneration to technical and auxiliary personnel	Total 2021	194.836
1.3) Other current expenses	Fewer than 250 employees	245.624
1.3) Other current expenses	250 or more employees	178.061
1.3) Other current expenses	Total 2021	423.685
2) By nature of the expense: Capital expenses	Fewer than 250 employees	61.458
2) By nature of the expense: Capital expenses	250 or more employees	37.033
2) By nature of the expense: Capital expenses	Total 2021	98.492
2.1) Land and buildings	Fewer than 250 employees	7.788
2.1) Land and buildings	250 or more employees	2.411
2.1) Land and buildings	Total 2021	10.199
2.2) Equipment and instruments	Fewer than 250 employees	40.235
2.2) Equipment and instruments	250 or more employees	32.349
2.2) Equipment and instruments	Total 2021	72.584
2.3) Acquisition of specific R&D software	Fewer than 250 employees	3.600
2.3) Acquisition of specific R&D software	250 or more employees	2.121
2.3) Acquisition of specific R&D software	Total 2021	5.721
2.4) Otros productos de propiedad intelectual específicos para I+D	Fewer than 250 employees	9.835
2.4) Otros productos de propiedad intelectual específicos para I+D	250 or more employees	152
2.4) Otros productos de propiedad intelectual específicos para I+D	Total 2021	9.987
1.1) By origin of the funds: Own funds	Fewer than 250 employees	403.266
1.1) By origin of the funds: Own funds	250 or more employees	308.222
1.1) By origin of the funds: Own funds	Total 2021	711.488
1.2) By origin of the funds: From companies	Fewer than 250 employees	75.949
1.2) By origin of the funds: From companies	250 or more employees	45.789
1.2) By origin of the funds: From companies	Total 2021	121.738
1.3) By origin of the funds: Public Administration funds	Fewer than 250 employees	76.924
1.3) By origin of the funds: Public Administration funds	250 or more employees	30.552
1.3) By origin of the funds: Public Administration funds	Total 2021	107.477
1.4) By origin of the funds: From Universities	Fewer than 250 employees	192
1.4) By origin of the funds: From Universities	250 or more employees	0
1.4) By origin of the funds: From Universities	Total 2021	192
1.5) By origin of the funds: From non profit private institutions	Fewer than 250 employees	1.543
1.5) By origin of the funds: From non profit private institutions	250 or more employees	9.213
1.5) By origin of the funds: From non profit private institutions	Total 2021	10.756
1.6) By origin of the funds: Foreign funds	Fewer than 250 employees	35.570
1.6) By origin of the funds: Foreign funds	250 or more employees	51.360
1.6) By origin of the funds: Foreign funds	Total 2021	86.931
Purchase of R&D services in biotechnology (thousands of euros)	Fewer than 250 employees	75.599
Purchase of R&D services in biotechnology (thousands of euros)	250 or more employees	69.958
Purchase of R&D services in biotechnology (thousands of euros)	Total 2021	145.557
Purchase of R&D services in biotechnology (thousands of euros): In Spain	Fewer than 250 employees	53.934
Purchase of R&D services in biotechnology (thousands of euros): In Spain	250 or more employees	41.981
Purchase of R&D services in biotechnology (thousands of euros): In Spain	Total 2021	95.915
Purchase of R&D services in biotechnology (thousands of euros): Abroad	Fewer than 250 employees	21.665
Purchase of R&D services in biotechnology (thousands of euros): Abroad	250 or more employees	27.977
Purchase of R&D services in biotechnology (thousands of euros): Abroad	Total 2021	49.642
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital	Fewer than 250 employees	42,3
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital	250 or more employees	23,7
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital	Total 2021	40,2
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information	Fewer than 250 employees	13,1
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information	250 or more employees	13,9
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information	Total 2021	13,2
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources	Fewer than 250 employees	19,4
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources	250 or more employees	16
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources	Total 2021	19
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain	Fewer than 250 employees	11
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain	250 or more employees	15,3
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain	Total 2021	11,5
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets	Fewer than 250 employees	16,5
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets	250 or more employees	10,4
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets	Total 2021	15,9
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels	Fewer than 250 employees	17,8
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels	250 or more employees	10,4
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels	Total 2021	17
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception	Fewer than 250 employees	16,1
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception	250 or more employees	19,5
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception	Total 2021	16,4
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements	Fewer than 250 employees	41,2
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements	250 or more employees	34,8
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements	Total 2021	40,5
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost	Fewer than 250 employees	56,1
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost	250 or more employees	46,5
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost	Total 2021	55
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting	Fewer than 250 employees	22,3
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting	250 or more employees	18,7
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting	Total 2021	21,9
% Companies with income of an international origin related to biotechnological activities	Fewer than 250 employees	24,2
% Companies with income of an international origin related to biotechnological activities	250 or more employees	18,1
% Companies with income of an international origin related to biotechnological activities	Total 2021	23,5
% Turnover representing income of an international origin related to biotechnological activities	Fewer than 250 employees	10,6
% Turnover representing income of an international origin related to biotechnological activities	250 or more employees	0,8
% Turnover representing income of an international origin related to biotechnological activities	Total 2021	1,9
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU	Fewer than 250 employees	56
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU	250 or more employees	69,8
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU	Total 2021	61,6
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries	Fewer than 250 employees	44
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries	250 or more employees	30,2
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries	Total 2021	38,4
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services	Fewer than 250 employees	93,8
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services	250 or more employees	78,7
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services	Total 2021	87,6
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Fewer than 250 employees	4,9
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	250 or more employees	19,6
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Total 2021	10,9
% Income of an international origin related with activities according to the classification: Operating source abroad	Fewer than 250 employees	0,6
% Income of an international origin related with activities according to the classification: Operating source abroad	250 or more employees	1,8
% Income of an international origin related with activities according to the classification: Operating source abroad	Total 2021	1,1
% Income of an international origin related with activities according to the classification: Other	Fewer than 250 employees	0,6
% Income of an international origin related with activities according to the classification: Other	250 or more employees	0
% Income of an international origin related with activities according to the classification: Other	Total 2021	0,4